Arterial hypertension, main side effect of anti-angiogenic drugs and possible early marker of efficiency

被引:0
|
作者
Levy, Bernard [1 ]
机构
[1] Hop Lariboisiere, Inst Vaisseaux & Sang, F-75010 Paris, France
来源
SANG THROMBOSE VAISSEAUX | 2013年 / 25卷 / 06期
关键词
anti-angiogenic drug; hypertension; side effects; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; BEVACIZUMAB; CANCER; TRIAL;
D O I
10.1684/stv.2013.0808
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-angiogenic drugs were introduced in oncology for less than 10 years and have become essential in combination with conventional chemotherapy. Vascular and cardiac side effects are the most frequent, at the forefront of which include high blood pressure which, according to studies, has an incidence of 10 to 40%. In the vast majority of cases, hypertension is not severe and remains easy to treat. However, reported cases thankfully rare but not exceptional of leuco-encephalopathy are associated with episodes of malignant hypertension; reversible on discontinuation of treatment. The pathophysiology of this high blood pressure secondary to anti-angiogenic therapy is discussed and proposed by many authors, as a simple early marker of the efficiency of the anti-angiogenic treatment.
引用
收藏
页码:399 / 404
页数:6
相关论文
共 29 条
  • [21] Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results
    Michael Fenchel
    Marina Konaktchieva
    Katja Weisel
    Sabina Kraus
    Harald Brodoefel
    Claus D. Claussen
    Marius Horger
    [J]. European Radiology, 2010, 20 : 2899 - 2906
  • [22] P1.1 Anti-Angiogenic Treatment in Cancer Patients Causes Arterial Dilation and Stiffening Beyond the Blood Pressure Effect
    B. Spronck
    A. De Lepper
    M. Alivon
    P. Boutouyrie
    K. Reesink
    [J]. Artery Research, 2014, 8 (4) : 129 - 129
  • [23] Effectiveness and safety of the treatment with oral propranolol in patients with hereditary hemorrhagic telangiectasia and blood hypertension or atrial fibrillation: A possible anti-angiogenic treatment in epistaxis
    Patier, J. L.
    Camacho Aguirre, A.
    Sirgo, N.
    Gonzalez Nino, I
    Suarez Carantona, C.
    Gonzalez Garcia, A.
    Lopez Rodriguez, M.
    Botella, L. M.
    [J]. ANGIOGENESIS, 2019, 22 (04) : 628 - 628
  • [24] Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA)
    Pesek, Milos
    Lucie, Benesova
    Svaton, Martin
    Belsanova, Barbora
    Ptackova, Renata
    Fiala, Ondrej
    Minarik, Masrek
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [25] Vascular and renal effects of anti-angiogenic medicines: French recommendations for practice (Nephrology Society, French Arterial Hypertension Society, National Pedagogical Association for therapeutic teaching and Francophone Federation of digestive cancerology)
    Halimi, Jean-Michel
    Azizi, Michel
    Bobrie, Guillaume
    Bouche, Olivier
    Deray, Gilbert
    des Guetz, Gaetan
    Lecomte, Thierry
    Levy, Bernard
    Mourad, Jean-Jacques
    Nochy, Dominique
    Oudard, Stephane
    Rieu, Philippe
    Sahali, Dil
    [J]. SANG THROMBOSE VAISSEAUX, 2009, 21 (03): : 151 - 166
  • [26] Amlodipine modulation of analgesic effect of non-steroidal anti-inflammatory drugs in rheumatoid arthritis, comorbid with arterial hypertension
    Seredynska, N. M.
    Kornienko, V., I
    Kibkalo, D., V
    Suvorova, O. S.
    Marchenko, O. M.
    Ladogubets, O., V
    [J]. REGULATORY MECHANISMS IN BIOSYSTEMS, 2020, 11 (04) : 557 - 562
  • [27] Vascular and renal effects of anti-angiogenic drugs: recommendations for French practice. (The Company of Nephrology, American Society of Hypertension, National Educational Association of Teachers of Therapeutics and Francophone Federation of Digestive Cancerology)
    Halimi, J. -M.
    Azizi, M.
    Bobrie, G.
    Bouche, O.
    Deray, G.
    des Guetz, G.
    Lecomte, T.
    Levy, B.
    Mourad, J. -J.
    Nochy, D.
    Oudard, S.
    Rieu, P.
    Sahali, D.
    [J]. ONCOLOGIE, 2009, 11 (9-10) : 476 - 489
  • [28] A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors
    Thomas, Markus
    Kienast, Yvonne
    Scheuer, Werner
    Baehner, Monika
    Kaluza, Klaus
    Gassner, Christian
    Herting, Frank
    Brinkmann, Ulrich
    Seeber, Stefan
    Kavlie, Anita
    Welschof, Martin
    Ries, Stefan
    Weidner, K. Michael
    Regula, Joerg T.
    Klein, Christian
    [J]. PLOS ONE, 2013, 8 (02):
  • [29] Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies
    Thomas, Markus
    Kienast, Yvonne
    Scheuer, Werner
    Lorenzon, Erica
    Herting, Frank
    Odin, Marielle
    Schaefer, Wolfgang
    Regula, Joerg Thomas
    Stubenrauch, Kay-Gunnar
    Klein, Christian
    [J]. CANCER RESEARCH, 2012, 72